Lung cancer genetic mutation screening for known oncogenes—epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements—were ordered to evaluate whether the tumor could be treated with tyrosine kinase inhibitors, such as erlotinib and crizotinib. This evidence concerns the gene EGFR and lung cancer.